Striant®
(TESTOSTERONE BUCCAL SYSTEM)
Striant® is indicated for men who require testosterone replacement therapy for a deficiency or absence of endogenous testosterone associated with hypogonadism.
> View the Striant Product Page for more information
Edex®
(alprostadil for injection)
Edex® is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
> View the Edex Product Page for more information
Theo-24®
(theophylline anhydrous)
Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
> View the Theo-24 Product Page for more information
Dilatrate®-SR
(isosorbide dinitrate)
Dilatrate®-SR sustained release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled- release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.
Levatol® tablets
(penbutolol sulfate)
Levatol® is indicated in the treatment of mild to moderate arterial hypertension. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
Robaxin®
(methocarbamol tablets, USP)
Robaxin® and Robaxin®-750 are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.
Semprex®-D Capsules
(acrivastine and pseudoephedrine hydrochloride)
Semprex®-D Capsules are indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus,lacrimation, and nasal congestion. Semprex-D Capsules should be administered when both the antihistaminic activity of acrivastine and the nasal decongestant activity of pseudoephedrine are desired (see CLINICAL PHARMACOLOGY). The efficacy of Semprex-D Capsules beyond 14 days of continuous treatment in patients with seasonal allergic rhinitis has not been adequately investigated in clinical trials. Semprex-D Capsules have not been adequately studied for effectiveness in relieving the symptoms of the commoncold.